Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Enter your email address below and subscribe to our newsletter

Lumibird Medical has unveiled its latest innovation, the C.DIAG, marking a significant advancement in dry eye diagnostic technology. Integrated with AI algorithms, this new component of the C.SUITE is designed to enable the diagnosis, treatment, and education of dry eye…

Topcon Healthcare has announced an investment in RetiSpec, marking the beginning of a collaboration aimed at commercializing RetiSpec’s innovative technology. This partnership intends to bridge the gap between neurology and eye care, potentially transforming how Alzheimer’s disease is detected and…

AEYE Health has received FDA clearance for its fully autonomous AI, making it the first to diagnose referable diabetic retinopathy using a handheld camera. The technology, known as AEYE Diagnostic Screening (AEYE-DS), was previously approved for use with a tabletop…

In the field of ophthalmology, laser technology is used in many basic and clinical disciplines and specialities. It has played an important role in promoting the development of ophthalmology. Advancements in technology have allowed improvements in the surgical safety, efficacy, speed…

AsclepiX Therapeutics announced the completion of a $10 million Series A-3 financing aimed at advancing the clinical development of its leading candidate, AXT107 (gersizangitide), in patients diagnosed with wet AMD. “With the completion of this round, we are excited to…

Scientists have developed computer models of patients’ eyes to determine the most suitable intraocular lenses and to offer patients a visual simulation of their expected vision with these lenses. Although millions of individuals have undergone LASIK eye surgery since it…

Astellas Pharma has signed a license agreement that grants them the rights to utilize the intravitreal retinotropic R100* vector, developed by 4D Molecular Therapeutics (4DMT). This agreement enables Astellas to target one specific genetic target associated with rare monogenic ophthalmic…

Researchers have successfully developed a groundbreaking synthetic protein to treat macular degeneration and other currently incurable eye diseases leading to blindness in millions of individuals. This pioneering drug, currently undergoing human trials, is the first of its kind. With over…

After observing discouraging phase 2 clinical data, Novartis has opted to terminate the clinical advancement of its geographic atrophy gene therapy candidate GT005, a product it acquired through the acquisition of Gyroscope Therapeutics. The announcement was officially disseminated by investment…

Ascertain, a joint venture between Aegis Ventures and Northwell Holdings, has raised $12 million in seed funding to launch Optain, an AI company that utilizes retinal imaging for early disease detection and prevention. Optain’s AI technology analyzes data from a…